Compare Amylx Pharmaceuticals Inc (AMLX) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Marathon Petroleum Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Marathon Petroleum Corp trades at $288 (market cap $82.83B). The key difference: Marathon Petroleum Corp is far larger — about 41.8× Amylx Pharmaceuticals Inc's market cap, and Marathon Petroleum Corp pays a 1.38% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MPC | |
|---|---|---|
Market Cap | $1.98B | $82.83B |
Sector | Health | Energy |
52-Week High | $18.70 | $283.74 |
52-Week Low | $7.64 | $158.59 |
Enterprise Value | $1.70B | $115.01B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Marathon Petroleum (MPC) trades at $283.74, up 0.16% with a bullish technical outlook supported by moving averages. The stock shows strong profitability with 27.92% ROE and attractive valuation metrics including P/E of 18.68 and P/S of 0.63. Recent earnings beat expectations in Q4 2025 and Q1 2026, while refining capacity constraints and Middle East tensions provide tailwinds for the energy sector.
MPC presents a compelling value opportunity with solid fundamentals and positive analyst sentiment, though investors face risks from volatile oil prices, regulatory scrutiny over pricing practices, and declining revenue trends. The stock trades near analyst consensus target of $278.38 with 76% buy ratings supporting upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
